NeuroMab™ Anti-PSK9 Antibody(NRP-0422-P1553)

Product Overview

Description

The antibody specifically bind and neutralize human PCSK9 (hPCSK9) activity, and can be used for treating hypercholesterolemia.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Human

Applications

WB; Inhib; Block; In Vitro; In Vivo; Neut

Application Notes

BACE1

Relevant Diseases

Alzheimer's Disease; Stroke; Neuroinflammation

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

> 95% (SDS-PAGE)

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

PSK9

Official Name

PCSK9

Full Name

Proprotein Convertase Subtilisin/Kexin Type 9

Alternative Names

Proprotein Convertase Subtilisin/Kexin Type 9; Subtilisin/Kexin-Like Protease PC9; NARC-1; NARC1; PC9; Convertase Subtilisin/Kexin Type 9 Preproprotein; Hypercholesterolemia; Autosomal Dominant 3; Neural Apoptosis Regulated Convertase 1; Neural Apoptosis-Regulated Convertase 1;

Gene ID

100102(Human)

Uniprot ID

Q80W65(Human)

Product Pictures

Figure 1 Western blot of LDL receptor in mouse whole liver homogenate. Samples taken 24 hours after administration of PBS (lanes 1-3), 5 mg/kg 316P (lanes 4-6), or 5 mg/kg non-hPCSK9-specific mAb (lanes 7-8) and 4 hours after administration of 1.2 mg /kg hPCSK9-mmh (all channels).

FuncS

Figure 10. Time-dependent changes in antibody concentrations in serum following single subcutaneous administration. 316P 5 mg/kg (●); 300N 5 mg/kg (σ).

FuncS

Figure 2 Effect of 316P on serum low-density lipoprotein cholesterol levels in PCSK9hu/hu mice. Buffer Control Chart US08357371-20130122-P00001 316P 1 mg/kg (.) 316P 5 mg/kg (.); 316P 10 mg/kg (.).

FuncS

Figure 3 Serum pharmacokinetic profile of anti-hPCSK9 mAb in C57BL/6 mice. Single dose control I mAb (λ) at 10 mg/kg; 316P (σ) at 10 mg/kg and 300N (ν) at 10 mg/kg.

FuncS

Figure 4. Serum pharmacokinetic profile of anti-hPCSK9 mAb in hPCSK9 heterozygous mice. Single dose control I mAb (λ) at 10 mg/kg; 316P (σ) at 10 mg/kg and 300N (ν) at 10 mg/kg.

FuncS

Figure 5 Effect of 316P on serum low-density lipoprotein cholesterol level in Syrian hamsters fed with normal diet. Buffer Control (●); 316P 1 mg/kg (ν); 316P 3 mg/kg (σ); 316P 5 mg/kg (τ).

FuncS

Figure 6 Serum total cholesterol levels as a percentage of change from buffer control. Buffer Control (T); 316P 5 mg/kg (ν); 300N 5 mg/kg (σ); 316P 15 mg/kg (□); 300N 15 mg/kg (Δ).

FuncS

Figure 7 Serum LDL cholesterol levels as percent change in buffer control: buffer control (T); 316P 5 mg/kg (ν); 300N 5 mg/kg (σ); 316P 15 mg/kg (□) ; 300N 15 mg/kg (Δ).

FuncS

Figure 8 Serum HDL cholesterol levels as a percent change from buffer control. Buffer Control (T); 316P 5 mg/kg (ν); 300N 5 mg/kg (σ); 316P 15 mg/kg (□); 300N 15 mg/kg (Δ).

FuncS

Figure 9 Serum triglyceride levels expressed as percent change from buffer control. Buffer Control (T); 316P 5 mg/kg (ν); 300N 5 mg/kg (σ); 316P 15 mg/kg (□); 300N 15 mg/kg (Δ).

Publications